ArticleBMC public health2026
Epidemiological and clinical characteristics of hospitalized patients with cardiomyopathies in China: a nationwide retrospective analysis.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCardiomyopathies are major causes of heart failure and sudden cardiac death, but nationwide epidemiological data from China remain limited. Following the inclusion of several cardiomyopathies in the first national rare disease list in 2018, contemporary trends in hospitalization and in-hospital outcomes have not been systematically evaluated. This study aimed to characterize national hospitalization patterns for cardiomyopathies from 2018 to 2022.
methodsWe conducted a nationwide retrospective study using the Hospital Quality Monitoring System (HQMS), which covers secondary and tertiary hospitals across 31 provinces. Cardiomyopathies were identified using National Clinical Version 2.0 codes. We assessed age- and sex-standardized hospitalization rates, regional variation, comorbidities, device use, intensive care unit (ICU) admission, in-hospital mortality, length of stay, and hospital costs. Temporal trends were analyzed using Joinpoint regression to estimate the average annual percent change (AAPC).
resultsA total of 1,935,421 hospitalizations from 943,178 unique patients were included. The standardized hospitalization rate increased from 151.55 to 206.23 per 1,000,000 population (AAPC = 7.68%). Dilated cardiomyopathy was the most frequently recorded subtype. Men accounted for 67.99% of patients and were diagnosed at a younger age than women. Considerable provincial variation was observed. ICU admission increased from 2.49% to 6.97% (AAPC = 33.94%, p = 0.01), while in-hospital mortality remained stable (0.85% to 0.89%; AAPC = - 0.03%, p = 0.96). Median length of stay decreased from 8 to 7 days (AAPC = - 2.91%, p = 0.03), and median hospital costs increased from CNY 7,362 to 7,985 (AAPC = 2.13%, p = 0.03).
conclusionsCardiomyopathy hospitalizations in China increased markedly between 2018 and 2022, with notable sex, age, and regional disparities. Rising ICU utilization alongside stable mortality suggests evolving case mix and improvements in acute care. These nationwide findings highlight unmet diagnostic and healthcare needs.
trial registrationClinical trial number: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.